logo-loader
viewBraveheart Investment Group

Braveheart Inv Group - Results of customer trials by Pharm2Farm Limited

RNS Number : 8709M
Braveheart Investment Group plc
19 September 2019
 

19 September 2019

Braveheart Investment Group plc

("Braveheart" or the "Group")

 

Results of customer trials by Pharm2Farm Limited

 

Braveheart Investment Group plc (AIM: BRH), the fund management and strategic investment group, is pleased to report that Pharm2Farm Limited ("Pharm2Farm"), an investee company in which Braveheart has a 33 per cent. interest has completed product trials with Griin Agriculture Co. ("Griin") in Korea. In these trials, Griin used its proprietary vertical hydroponic system, designed to grow the herb basil intensively in indoor, inner city locations.

 

The Korean team compared plants grown indoors, under controlled conditions. Plants grew much faster and had an improved taste when Pharm2Farm nanoparticles were added to their nutrient feeds.

 

Over a 20 day harvesting period, the treated plants produced 33 per cent. more leaves with more intense taste than the untreated plants. Griin sells the basil to local shops and restaurants, who value the high quality, freshness, low miles and eco-friendly nature. Customers appreciate that fresh vegetables taste better and research shows that some produce loses more than 50 per cent. of its nutrition within days of harvesting.

 

Trace minerals, such as iron, copper, silicon, are essential for healthy plant growth, but historically they have been difficult to incorporate into a fertilizer in a form which can be readily taken up by plants.

 

Pharm2Farm's coated nanoparticle technology, has been demonstrated to dramatically increase the bioavailability of trace minerals in plant feeds applicable to all areas of the farming market.

 

For further information:

 

Braveheart Investment Group plc
Trevor Brown, Chief Executive Officer

 

 

Tel: 01738 587555

Allenby Capital Limited (Nominated Adviser and Joint Broker)
David Worlidge / Nicholas Chambers

 

Tel: 020 3328 5656

 

 

Peterhouse Capital Limited (Joint Broker)
Heena Karani / Lucy Williams

 

 

Tel: 020 7469 0936

 

About RNS Reach Announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAGGUWPBUPBGQR

Quick facts: Braveheart Investment Group

Price: 8.5

Market: AIM
Market Cap: £2.39 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Braveheart's Trevor Brown details investment in 'exciting' Pharm2Farm Limited

Proactive London's Andrew Scott speaks to Braveheart Investment Group PLC's (LON:BRH) and Pharm2Farm Limited's (P2F) Gareth Cave following Braveheart's investment in the business. P2F has developed a patented process to increase the bioavailability of trace minerals in plant feeds for...

on 15/7/19